American Bio Medica Corporation

Equities

ABMC

US0246001087

Medical Equipment, Supplies & Distribution

Delayed OTC Markets Other stock markets 08:54:49 21/06/2024 pm IST			5-day change	1st Jan Change
0.0001 ^USD	0.00%		0.00%	0.00%

2023	American Bio Medica Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
2023	American Bio Medica Corporation Auditor Raises 'Going Concern' Doubt	CI

American Bio Medica Corp. Reports Earnings Results for the Full Year Ended December 31, 2018

April 17, 2019 at 02:38 am IST

American Bio Medica Corp. announced earnings results for the full year ended December 31, 2018. For the full year, the company announced sales was USD 3.872 million compared to USD 4.914 million a year ago. Operating loss was USD 762,000 compared to USD 311,000 a year ago. Net loss was USD 1.028 million compared to USD 545,000 a year ago. Basic loss per share was USD 0.03 compared to USD 0.02 a year ago.

Latest news about American Bio Medica Corporation

American Bio Medica Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	13/23/13	CI
American Bio Medica Corporation Auditor Raises 'Going Concern' Doubt	21/23/21	CI
American Bio Medica Corporation Announces Termination of Melissa A. Waterhouse as Principal Financial Officer	02/23/02	CI
American Bio Medica Corporation Announces Termination of Melissa A. Waterhouse as Chief Executive Officer	02/23/02	CI
Healgen Scientific LLC completed the acquisition of substantially all of the operating assets of American Bio Medica Corporation.	28/23/28	CI
Healgen Scientific LLC agreed to acquire substantially all of the operating assets of American Bio Medica Corporation for $3 million.	21/22/21	CI
American Bio Medica Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	17/22/17	CI
American Bio Medica Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	16/22/16	CI
American Bio Medica Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	17/22/17	CI
American Bio Medica Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	15/22/15	CI
American Bio Medica Corporation Auditor Raises 'Going Concern' Doubt	15/22/15	CI
American Bio Medica Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	19/21/19	CI
American Bio Medica Corporation announced that it has received $0.1 million in funding	18/21/18	CI
Declaration of Voting Results by American Bio	30/21/30	CI
John J. Moroney Engages in Discussions with American Bio Medica	02/21/02	CI
American Bio Medica Corporation Reports Earnings Results for the First Quarter Ended March 31, 2021	21/21/21	CI
Earnings Flash (ABMC) AMERICAN BIO MEDICA CORPORATION Reports Q1 Loss $-0.01	21/21/21	MT
American Bio Medica Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2020	15/21/15	CI
American Bio Medica Corporation Announces Resignation of Chaim Davis from the Board of Directors	12/21/12	CI
American Bio Medica Corporation announced that it expects to receive $0.125 million in funding from Lincoln Park Capital, LLC	10/20/10	CI
American Bio Medica Corporation Reports Earnings Results for the Third Quarter Ended September 30, 2020	17/20/17	CI
American Bio Medica : Earnings Flash (ABMC) AMERICAN BIO MEDICA CORPORATION Posts Q3 EPS $-0.01	17/20/17	MT
American Bio Medica Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2020	16/20/16	CI
American Bio Medica Corporation Reports Earnings Results for the First Quarter Ended March 31, 2020	01/20/01	CI
American Bio Medica Corporation Reports Earnings Results for the Full Year Ended December 31, 2019	27/20/27	CI

Chart American Bio Medica Corporation

Duration

Period

More charts

Company Profile

American Bio Medica Corporation is engaged in the manufacturing and distribution of lateral flow immunoassay tests, primarily for the immediate detection of drugs in urine and oral fluid. The Company also distributes a number of other products related to the immediate detection of drugs and alcohol. It manufactures a number of products that detect the presence or absence of drugs in urine. It manufactures the various urine drug testing product lines, including The Rapid Drug Screen (RDS), RDS InCup, Rapid TOX, Rapid TOX Cup and Private Label Products. RDS is a patented rapid drug test that detects the presence or absence of 2-10 drugs simultaneously in a single urine specimen. RDS InCup is a drug-testing cup that detects the presence or absence of 1-12 drugs in a urine specimen. Its OralStat is a drug test for the detection of drugs in oral fluids. Its Respiratory Syncytial Virus (RSV) test does detect RSV in both children under the age of six, as well as adults over the age of 60.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Income Statement Evolution

More financial data

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
AMERICAN BIO MEDICA CORPORATION	0.00%	4.81K
BIOMÉRIEUX	-11.38%	11.41B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-12.48%	7.4B
LANTHEUS HOLDINGS, INC.	+30.83%	5.64B
DIASORIN S.P.A.	-0.45%	5.33B
AUTOBIO DIAGNOSTICS CO., LTD.	-19.19%	3.7B
ANDON HEALTH CO., LTD.	+7.43%	2.58B
10X GENOMICS, INC.	-64.67%	2.38B
VITROLIFE AB	-10.73%	2.2B
MYRIAD GENETICS, INC.	+26.23%	2.2B

Diagnostic & Testing Substances